Literature DB >> 36175778

TNFAIP3 promotes ALDH-positive breast cancer stem cells through FGFR1/MEK/ERK pathway.

Wanru Feng1, Mengdi Gao1, Mao Yang1, Xue Li1, Zhonglin Gan1, Ting Wu1, Yan Lin1, Tao He2.   

Abstract

Breast cancer stem cells (BCSCs) are a tiny population of self-renewing cells that may contribute to cancer initiation, progression, and resistance to therapy in patients. In our prior study, we found that tumor necrosis factor alpha-induced protein 3 (TNFAIP3) is necessary for fibroblast growth factors receptor 1 (FGFR1) signaling-promoted tumor growth and progression in breast cancer (BC). This study aims to investigate the involvement of TNFAIP3 in regulating BCSCs. In this work, we showed that ALDH-positive BCSCs were increased by activating the FGFR1-MEK-ERK pathway, meanwhile utilizing FGFR1 inhibitor, MEK inhibitor, or ERK inhibitor reversed the phenomenon in BC cells. Moreover, ALDH-positive BCSCs were decreased in TNFAIP3-knockout or TNFAIP3-depressing cells. In vivo analysis displayed that TNFAIP3-silenced MDA-MB-231 xenografts developed smaller tumors and ALDH immunostaining levels were significantly lower in TNFAIP3-depressing or TNFAIP3-knockout tumor tissues. Besides, our results also revealed that TNFAIP3 influences the transcription stemness factors gene expression. Taken together, TNFAIP3 could be a potential regulator in FGFR1-MEK-ERK-promoted ALDH-positive BCSCs.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  BCSCs; Breast cancer; FGFR1; TNFAIP3

Mesh:

Substances:

Year:  2022        PMID: 36175778     DOI: 10.1007/s12032-022-01844-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.738


  39 in total

1.  Cancer Statistics, 2021.

Authors:  Rebecca L Siegel; Kimberly D Miller; Hannah E Fuchs; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2021-01-12       Impact factor: 508.702

Review 2.  Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance.

Authors:  Hariharan Easwaran; Hsing-Chen Tsai; Stephen B Baylin
Journal:  Mol Cell       Date:  2014-06-05       Impact factor: 17.970

3.  Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma.

Authors:  Osamu Maehara; Goki Suda; Mitsuteru Natsuizaka; Shunsuke Ohnishi; Yoshito Komatsu; Fumiyuki Sato; Masato Nakai; Takuya Sho; Kenichi Morikawa; Koji Ogawa; Tomoe Shimazaki; Megumi Kimura; Ayaka Asano; Yoshiyuki Fujimoto; Shinya Ohashi; Shingo Kagawa; Hideaki Kinugasa; Seiji Naganuma; Kelly A Whelan; Hiroshi Nakagawa; Koji Nakagawa; Hiroshi Takeda; Naoya Sakamoto
Journal:  Carcinogenesis       Date:  2017-10-26       Impact factor: 4.944

Review 4.  Breast cancer.

Authors:  Nadia Harbeck; Michael Gnant
Journal:  Lancet       Date:  2016-11-17       Impact factor: 79.321

Review 5.  Advances and challenges in targeting FGFR signalling in cancer.

Authors:  Irina S Babina; Nicholas C Turner
Journal:  Nat Rev Cancer       Date:  2017-03-17       Impact factor: 60.716

Review 6.  Trailblazing perspectives on targeting breast cancer stem cells.

Authors:  Juntao Li; Dan Qi; Tze-Chen Hsieh; Jason H Huang; Joseph M Wu; Erxi Wu
Journal:  Pharmacol Ther       Date:  2021-01-07       Impact factor: 12.310

7.  Fibroblast growth factor (FGF) signaling regulates transforming growth factor beta (TGFβ)-dependent smooth muscle cell phenotype modulation.

Authors:  Pei-Yu Chen; Lingfeng Qin; Guangxin Li; George Tellides; Michael Simons
Journal:  Sci Rep       Date:  2016-09-16       Impact factor: 4.379

Review 8.  Breast Cancer Treatment: A Review.

Authors:  Adrienne G Waks; Eric P Winer
Journal:  JAMA       Date:  2019-01-22       Impact factor: 56.272

Review 9.  Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.

Authors:  Teresa Helsten; Maria Schwaederle; Razelle Kurzrock
Journal:  Cancer Metastasis Rev       Date:  2015-09       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.